|
Real-time Estimate
Cboe BZX
12:19:55 2026-10-28 EDT
|
5-day change | 1st Jan Change | ||
| 1,284.99 USD | +0.24% |
|
+1.59% | +20.13% |
| 10:52am | Eli Lilly Says Retatrutide Delivers Greater Weight Loss Than Ozempic in Adults With Type 2 Diabetes | MT |
| 10:14am | Diabetes and obesity: Eli Lilly's Retatrutide outperforms Ozempic in Phase 3 |  |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ELI LILLY AND COMPANY | Other Pharmaceuticals | +0.76% | +1.59% | +20.13% | +57.42% | +409.57% | 1,143B |  | | |
- Stock Market
- Stocks
- LLY Stock
- Charts Eli Lilly and Company
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
